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OBJECTIVES: The importance of patient-centered outcomes (PCO) in drug 
development is increasingly recognized by health authorities, clinical advisory 
and patient advocacy bodies. Accordingly, many of these organizations seek to 
include PCO in their guidelines and recommendations. However, complex 
disorders present measurement challenges that are difficult to resolve within the 
scope of a clinical trial (CT). An example is Systemic Lupus Erythematosus (SLE), 
characterized by myriad clinical indicator, symptom, severity and frequency 
combinations. SLE patient burden studies demonstrate that, while symptoms 
differ, the impact is universal. This study evaluates the relationship between 
recently updated SLE guidances and concepts reported directly by SLE patients. 
METHODS: A qualitative study comprised of six SLE patient focus groups (N=43) 
was conducted to elicit direct patient input on key symptoms and concepts. FDA 
and EMA guidelines for SLE clinical trials, European League Against Rheumatism 
(EULAR) CT endpoint recommendations, and the Systemic Lupus International 
Collaborating Clinics (SLICC) classification system were evaluated for PCO-
specific content. Patient-reported outcomes (PRO) concepts from the study were 
then compared to the PCO content from the guidelines and recommendations. 
RESULTS: All study subjects (mean age 44.3 years; 91.7% women; 63% diagnosed 
≥ 5 years; 91% experienced flare ≤ 3 months; 74% mild/moderate disease) 
identified fatigue among “most important symptoms” with 98% citing pain and 
44% fog/confusion. Regardless of “importance” all subjects deemed other 
symptoms highly disruptive. EMA and FDA both specify fatigue as a clinical trial 
endpoint. FDA included “fatigue” based on clinician input, but recommended 
development of a PRO-based fatigue exploratory endpoint. EULAR, citing 
challenges of symptom endpoints, suggested general Health-Related Quality of 
Life. The SLICC didn’t mention PCOs. CONCLUSIONS: Patients identified multiple 
SLE symptoms and impacts, yet guidances didn’t address these issues. Joint 
efforts between patients, sponsors, regulators and advisory organizations are 
necessary to implement relevant PCOs, especially in complex disorders.  
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OBJECTIVES: To compare clinical and cost characteristics among patients with 
inflammatory bowel disease (IBD) receiving biologic medication in an in-office 
setting (IOI), hospital outpatient department (HOPD), or ambulatory clinic. 
METHODS: A syndicated study of IBD patients was conducted. Patients aged ≥18 
years were recruited via the National Health and Wellness Survey and 
Lightspeed Research Panel to complete a survey during August–November 2010. 
Patients were asked about health care utilization, concomitant medications, IBD 
symptoms, quality of life (QoL) and out-of-pocket (OOP) costs. To measure 
utilization, the number of provider, emergency room (ER), and hospital visits in 
the past 6 months was collected. The Medical Outcomes Study (MOS) IBD 
questionnaire was used to assess QoL. Bivariate differences were assessed using 
Fisher’s exact tests for categorical variables and ANOVAs for continuous 
variables. RESULTS: Of 175 IBD patients, 54% (n=94) received biologic medication 
in an IOI setting, 35% (n=61) in an HOPD setting, and 11% (n=20) in an ambulatory 
clinic. The number of ER and hospital visits were similar across groups, however 
IOI patients had greater provider visits (p<0.05). Though concomitant medication 
utilization was generally similar, significantly more IOI patients received steroids 
compared to HOPD patients (p<0.05). Most IBD symptoms did not differ across 
groups. However, HOPD patients were more likely to have fistulas than IOI 
patients (30% vs. 16%; p<0.05), and IOI patients were less likely to experience 
bowel movements than HOPD or clinic patients (55% vs. 84% and 80%, 
respectively). HOPD patients had lower OOP costs for biologic medications and 
higher QoL scores compared to IOI patients (p<0.05). CONCLUSIONS: Among IBD 
patients receiving biologic medication in an IOI, HOPD, or ambulatory clinic 
setting, HOPD patients had higher QoL and lower OOP costs, however, few other 
differences were identified. Further research is needed to elucidate these 
findings.  
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OBJECTIVES: Deficits in physical health-related quality of life (HRQL) and sleep 
quality in chronic low back pain (CLBP) patients may be alleviated with 
Buprenorphine Transdermal System (BTDS) treatment. This post-hoc analysis of 
clinical trial data aimed to explore whether BTDS treatment has a direct impact 
on HRQL and sleep quality, an indirect impact on the outcomes as mediated 
through its impact of pain, or both; and to identify significant correlates of HRQL 
and sleep quality. METHODS: In this multicenter, enriched, double-blind, 
randomized trial, opioid-naïve patients with moderate-to-severe CLBP received 
twelve weeks’ treatment with BTDS (10 or 20 mcg/hour) or placebo. A series of 
multivariate linear regression models (stepwise) predicting physical HRQL, sleep 
disturbance, and sleep quality at week 12 were fitted. Physical HRQL was 
measured using the SF-36v2 Physical Component Summary (PCS), while sleep 
outcomes were measured using the Disturbance subscale and Sleep Problems 
Index (SPI) of the Medical Outcomes Study Sleep Scale (MOS-SS). For each 
outcome, models 1 and 2 included baseline demographic and clinical variables, 
model 3 added treatment arm, and model 4 added pain assessment at week 8. 
RESULTS: Results from model 3 supported BTDS treatment as a significant 
predictor of better physical HRQL and sleep outcomes. Model 4 results for each 
outcome indicated that pain was a partial mediator of treatment on physical 
HRQL and sleep quality, meaning that treatment had both direct and indirect 
effects on these outcomes. Mid-trial pain and the baseline value of the outcome 
being tested (i.e., PCS score, Disturbance score, or SPI score) were the strongest 
predictors for each outcome. CONCLUSIONS: For CLBP patients, improvements 
in physical HRQL, sleep disturbance, and sleep quality were impacted by BTDS 
treatment both directly as well as indirectly via mediation through the 
treatment-driven reductions in pain. Mid-trial pain strongly predicted to HRQL 
and sleep outcomes.  
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OBJECTIVES: Patients with moderate-to-severe chronic low back pain (CLBP) who 
are treated with Buprenorphine Transdermal System (BTDS) experience 
improvements in three patient-reported outcomes: quality of life (QoL), sleep 
quality, and functioning. This analysis compared the relative responsiveness of 
measures of each outcome to treatment and treatment-driven changes in pain. 
METHODS: This post-hoc analysis used data from an enriched, 12-week double-
blind, randomized placebo-controlled trial evaluating BTDS (10 or 20 mcg/hour) 
for treatment of pain in opioid-naive patients with moderate-to-severe CLBP. 
The trial repeatedly assessed QoL (SF-36v2), sleep quality and problems (Medical 
Outcomes Study Sleep Scale [MOS-SS]), and functional disability (Oswestry 
Disability Index [ODI]) in addition to measures of pain. Responsiveness of each 
instrument to treatment and changes in pain were examined using analysis of 
covariance, t-tests, and effect sizes for comparison of effects of time, treatment, 
and magnitude of pain reduction. The interrelation among PROs was also 
examined. RESULTS: The SF-36v2 and ODI showed better responsiveness to 
treatment and changes in pain than did the MOS-SS. Among subscales of the 
MOS-SS, only Disturbance showed substantial correlations with other PRO and 
pain measures and substantial differences across time, treatment, and pain 
reduction status groups. Several of the QoL domains measured by the SF-36v2, 
particularly Bodily Pain, Physical Functioning, Role Physical, Social Functioning, 
and Vitality, showed considerable responsiveness to treatment and pain. For the 
ODI, the Pain Intensity subscale showed the greatest responsiveness, with the 
majority of the remaining subscales showing more moderate, but still 
meaningful, levels of responsiveness. PRO measures were, in general, 
moderately inter-correlated, particularly between SF-36v2 and ODI subscales. 
CONCLUSIONS: Pain subscales on the SF-36v2 and ODI showed the greatest 
responsiveness to treatment. Substantial responsiveness was also observed for 
the majority of QoL and functioning domains, as well as sleep disturbance. 
Subscales of PRO instruments were generally moderately inter-correlated.  
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OBJECTIVES: Obesity has become a major public health problem worldwide. In 
Singapore, the prevalence of obesity among adults aged 18-69 years increased 
from 6.9% in 2004 to 10.8% in 2010. To the best of our knowledge, no single 
obesity-specific HRQoL instrument comprehensively covered areas of life that 
are important to obese individuals. Therefore we sought to assess the content 
validity of FABQOL, a newly developed instrument, to address the gap. 
METHODS: FABQOL (76 items) was developed based on literature review and 
mapped to obesity-specific International Classification of Functions Disability 
and Health (ICF) categories. Content validity (i.e. item comprehension and 
content coverage) was assessed through individual cognitive debriefing 
interviews with 30 English-speaking, ethnic Chinese, Malay and Indian 
overweight/obese patients from a weight management clinic at a public hospital 
in Singapore. For each item, we asked participants if the item was important to 
them (yes/no). Items that were perceived as not important by at least 50% of the 
participants and items that were not understood by at least 20% of the 
participants were removed. Participants were also asked to suggest additional 
items that were important. RESULTS: Participants aged from 23-58 years (median 
age = 45), one-third were men and 90% were obese (BMI>27.5kg/m2). Two items 
“being able to eat as much as I want to” and “being able to reach for objects 
placed above me” were perceived as not important by 26 (87%) and 15 (50%) of 
participants respectively. Four items (“lethargic”, “distressed”, “anxious” and 
“stigmatized”) were removed because they were poorly understood. Three 
participants suggested three new items pertaining to relationship with close 
friends, company image and personal leisure activities. CONCLUSIONS: The 
revised FABQOL comprises 73 items that were generally easy to understand and 
important to overweight/obese patients in Singapore. Psychometric properties of 
FABQOL will be evaluated in a larger study.  
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